Log In
BCIQ
Print this Print this
 

Mirapexin pramipexole prolonged release

  Manage Alerts
Collapse Summary General Information
Company Boehringer Ingelheim GmbH
DescriptionOnce-daily prolonged release formulation of Mirapexin, a dopamine agonist
Molecular Target Dopamine D2 receptor ; Dopamine D3 receptor (DRD3)
Mechanism of ActionDopamine D2 receptor agonist; Dopamine D3 receptor agonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationParkinson's disease (PD)
Indication DetailsTreat advanced Parkinson's disease (PD); Treat signs and symptoms of Parkinson's disease (PD)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today